20 July 2026
20 July 2026
The technology offers a dual-sided design with a nonporous underside and porous polyethylene structure on other sides.
The partnership’s initial activities will target cardiovascular and renal diseases, oncology, and women’s health.
The framework combines Aptar Pharma’s elastomeric experience and a network of partners across the injectable drugs sector.
The companies plan to modernise equipment across clinical areas such as cardiology, neurology, oncology, and women’s health.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
